Presentazione di PowerPoint

1
Patients Assignments,Values at Screening, and
Baseline Efficacy and Safety Values - PartI
JP Després, N Engl J Med 2005 353 2121-34
2
Patients Assignments,Values at Screening, and
Baseline Efficacy and Safety Values - PartII
JP Després, N Engl J Med 2005 353 2121-34
3
Changes from Baseline for the Efficacy and Safety
End Points in the Intention-to-Treat Population,
According to the Repeated-Measures (RM) Method
and Last-Observation-Carried-Forward
(LOCF)Analyses Part I
JP Després, N Engl J Med 2005 353 2121-34
4
Changes from Baseline for the Efficacy and Safety
End Points in the Intention-to-Treat Population,
According to the Repeated-Measures (RM) Method
and Last-Observation-Carried-Forward
(LOCF)Analyses Part II
JP Després, N Engl J Med 2005 353 2121-34
5
Effect of Placebo or Rimonabant for 52 Weeks on
Body Weight, Waist Circumference, Plasma
Triglyceride Levels, and High-Density
Lipoprotein (HDL) Cholesterol Levels
JP Després, N Engl J Med 2005 353 2121-34
6
Effect of Placebo or 20 mg of Rimonabant for 52
Weeks on the Plasma Glucose and Insulin Responses
to Oral Glucose Challenge (Panels A - B), and the
Plasma Adiponectin Level (Panels C - D)
JP Després, N Engl J Med 2005 353 2121-34
7
Adverse Events Part I
JP Després, N Engl J Med 2005 353 2121-34
8
Adverse Events Part II
JP Després, N Engl J Med 2005 353 2121-34